Patients with type 2 diabetes exhibit opposite changes in dopaminergic pathways compared to Group B. In contrast to Group B, the patient model with type 2 diabetes was found to have underexpression of LAT1 in the hyperglycemic condition (32). Here, SLC7A5 is linked to type 2 diabetes mellitus.